Internal Contact Information
Dr. Hitendra Patel is an Assistant Professor at University of Arizona College of Medicine and specializes in treatment of gastrointestinal cancers and skin cancers. He is the team leader of the Gastrointestinal Cancer Research Team at the University of Arizona Cancer Center.
Dr. Patel is board certified in Internal Medicine, Hematology and Oncology and has more than 10 years of experience treating these cancers. After finishing his Fellowship in Hematology and Oncology in 2005, he was faculty at University of Missouri-Kansas City School of Medicine (UMKC). At UMKC he mentored many medical students, Internal Medicine residents and Hematology/Oncology Fellows. He was Program Director of Hematology/Oncology Fellowship Program and Chair of Oncology Committee at UMKC in Kansas City.
He joined University of Arizona Cancer Center in 2012 and has been active in cancer treatment and research. He leads the research team focused on treatment and research of Gastrointestinal Cancer. He is the Chair of Data Safety Monitory Committee at the University of Arizona Cancer Center, which oversees issues related to safety of subjects involved in cancer clinical trials.
Dr. Patel’s goals is to achieve the best possible outcome in management of cancer while preserving quality of life. He is known to be a compassionate physician who spend as much time as it is needed to address any issue which arises during cancer treatment.
Click here to see a list of Dr. Patel's active clinical trials.
- Cantoria MJ, Patel H, Boros LG and Meuillet MJ; “Metformin and Pancreatic Cancer Metabolism” in Book titled “Pancreatic Cancer - Insights into Molecular Mechanisms and Novel Approaches to Early Detection and Treatment,” book edited by Dr. Kelly McCall, ISBN: 978-953-51-1375-1, Published May 2014
- Jacobs SA, Vidnovic N, Patel H, Soma LA, Chang Y, Bass N, Swerdlow SH; “Durable remission of HIV-negative, Kaposi’s sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate’’ ; Clin Rheumatol, 2006 Jul 6
- Patel H, Stoller R, Auber M, Potter D, Cai C, Zamboni W, Kiefer G, Matin K, Schmotzer A, Ramanathan RK; “Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy”; Invest New Drugs, 2006 Jul; 24 (4): 359-63
- Patel C, Jennings WH, Patel, H; “Laboratory Evaluation of Thrombophilia”; Missouri Medicine, January/February 2009; Vol. 106, Number 1: 55-59
- Haideri N, Patel H; “New Anticoagulants & Clinical Trials”, Missouri Medicine, January/February 2009; Vol. 106, Number 1: 60-64
- Samulitis BK, Pond K, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, Landowski TH. "Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther. 2014 Dec 8:0. [Epub ahead of print]
- Malangone S, Patel H, Kurtin SE, Tiwari HA, and Elquza, E, MD. Management of the Patient With Metastatic Colorectal Adenocarcinoma. J Adv Pract Oncol 2015;6:144–152
American Society of Clinical Oncology
American Society of Hematology
South Western Oncology Group (SWOG)